GlassScriptPhysician profile
Talha Aijaz
NPI 1225567233
$6,337.82
in general payments reported to CMS, 2019-2025
46 companies · $464 in 2025
The $464 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,074 · 2021: $1,995 · 2022: $1,821 · 2023: $938 · 2024: $45.06 · 2025: $464.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,448.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,447.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,006.28 | 2020-2023 | Lumakras, Kyprolis, Blincyto |
| Seagen INC. | $529.86 | 2021-2023 | Adcetris, Padcev |
| Eisai INC. | $511.04 | 2020-2022 | |
| Incyte Corporation | $458.61 | 2020-2022 | |
| Janssen Biotech, INC. | $374.31 | 2021-2025 | Erleada, Talvey, Tecvayli |
| Astrazeneca Pharmaceuticals LP | $308.38 | 2021-2023 | Lynparza, Tagrisso |
| Genzyme Corporation | $269.20 | 2021-2025 | |
| Daiichi Sankyo INC. | $205.05 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $191.29 | 2020-2025 | Keytruda, Lynparza, Welireg |
| Emd Serono, INC. | $175.33 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $172.63 | 2020-2023 | Opdivo |
| Rigel Pharmaceuticals, INC. | $172.13 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $148.24 | 2023-2025 | |
| Coherus Oncology, INC. | $140.86 | 2022-2023 | |
| Gilead Sciences, INC. | $133.91 | 2022-2023 | Trodelvy |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Talha Aijaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.